William S. Dalton

19.5k total citations · 4 hit papers
132 papers, 11.8k citations indexed

About

William S. Dalton is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, William S. Dalton has authored 132 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 60 papers in Oncology and 49 papers in Hematology. Recurrent topics in William S. Dalton's work include Multiple Myeloma Research and Treatments (44 papers), Drug Transport and Resistance Mechanisms (21 papers) and Cancer therapeutics and mechanisms (21 papers). William S. Dalton is often cited by papers focused on Multiple Myeloma Research and Treatments (44 papers), Drug Transport and Resistance Mechanisms (21 papers) and Cancer therapeutics and mechanisms (21 papers). William S. Dalton collaborates with scholars based in United States, Netherlands and Canada. William S. Dalton's co-authors include Terry H. Landowski, Lori Hazlehurst, Kenneth H. Shain, Richard Jove, Mark B. Meads, Robert A. Gatenby, Lynn C. Moscinski, Domenico Coppola, Marc M. Oshiro and Robyn Catlett-Falcone and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

William S. Dalton

130 papers receiving 11.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells

1999 1.4k citations Robyn Catlett-Falcone, Terry H. Landowski et al. Immunity profile →
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

2003 923 citations Tianhong Wang, Guilian Niu et al. Nature Medicine profile →
Environment-mediated drug resistance: a major contributor to minimal residual disease

2009 679 citations Mark B. Meads, William S. Dalton et al. profile →
MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA

2008 573 citations Domenico Coppola, William S. Dalton et al. Molecular and Cellular Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William S. Dalton United States	59	6.8k	5.7k	2.4k	2.3k	2.3k	132	11.8k
Pierfrancesco Tassone Italy	65	7.5k 1.1×	3.9k 0.7×	2.9k 1.2×	3.8k 1.6×	1.6k 0.7×	317	11.8k
Wee Joo Chng Singapore	58	7.2k 1.1×	3.6k 0.6×	4.0k 1.7×	1.6k 0.7×	1.6k 0.7×	386	11.3k
Ralf C. Bargou Germany	55	4.7k 0.7×	6.4k 1.1×	2.3k 1.0×	918 0.4×	3.2k 1.4×	178	11.7k
Atanasio Pandiella Spain	57	6.6k 1.0×	4.9k 0.9×	1.4k 0.6×	1.5k 0.7×	1.3k 0.6×	284	11.6k
Klaus Podar United States	63	8.7k 1.3×	4.6k 0.8×	6.6k 2.7×	1.3k 0.6×	1.8k 0.8×	186	12.8k
Anthony Letai United States	62	12.2k 1.8×	4.5k 0.8×	3.7k 1.5×	2.1k 0.9×	2.9k 1.3×	175	18.2k
Klas G. Wiman Sweden	67	9.3k 1.4×	7.0k 1.2×	694 0.3×	2.3k 1.0×	2.0k 0.9×	179	14.1k
Gary E. Gallick United States	67	7.7k 1.1×	6.0k 1.0×	1.2k 0.5×	2.9k 1.2×	1.0k 0.5×	202	13.7k
Joseph Lotem Israel	50	5.7k 0.8×	3.2k 0.6×	1.9k 0.8×	1.2k 0.5×	2.2k 1.0×	111	9.4k
Richard B. Lock Australia	53	5.1k 0.8×	2.8k 0.5×	1.6k 0.7×	1.2k 0.5×	1.0k 0.4×	260	8.7k

Countries citing papers authored by William S. Dalton

Since Specialization

Citations

This map shows the geographic impact of William S. Dalton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William S. Dalton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William S. Dalton more than expected).

Fields of papers citing papers by William S. Dalton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William S. Dalton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William S. Dalton. The network helps show where William S. Dalton may publish in the future.

Co-authorship network of co-authors of William S. Dalton

This figure shows the co-authorship network connecting the top 25 collaborators of William S. Dalton. A scholar is included among the top collaborators of William S. Dalton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William S. Dalton. William S. Dalton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Xuefeng, Vineeth Sukrithan, Aakrosh Ratan, et al.. (2023). Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.. Journal of Clinical Oncology. 41(16_suppl). 2617–2617. 2 indexed citations

Boucher, Kelly, Raymond Widen, Kenneth H. Shain, et al.. (2012). Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow. Clinical Cancer Research. 18(22). 6155–6168. 69 indexed citations

Yarde, Danielle N., Vasco Oliveira, Linda Mathews, et al.. (2009). Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma. Cancer Research. 69(24). 9367–9375. 90 indexed citations

Nair, Rajesh R., Michael F. Emmons, Anne E. Cress, et al.. (2009). HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Molecular Cancer Therapeutics. 8(8). 2441–2451. 33 indexed citations

Perez, Lia, et al.. (2009). Bortezomib restores stroma‐mediated APO2L/TRAIL apoptosis resistance in multiple myeloma. European Journal Of Haematology. 84(3). 212–222. 23 indexed citations

Nair, Rajesh R., et al.. (2008). Bone marrow stromal cells activate Stat3 and confer resistance to Bcr-Abl inhibitors in K562 CML cells. Cancer Research. 68. 2454–2454.

Oliveira, Vasco, William J. Romanow, Christoph Geisen, et al.. (2008). A Protective Role for the Human SMG-1 Kinase against Tumor Necrosis Factor-α-induced Apoptosis. Journal of Biological Chemistry. 283(19). 13174–13184. 37 indexed citations

Burdelya, Lyudmila G., Maciej Kujawski, Guilian Niu, et al.. (2005). Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects. The Journal of Immunology. 174(7). 3925–3931. 114 indexed citations

Valkov, Nikola, et al.. (2004). The cytoplasmic trafficking of DNA topoisomerase IIα correlates with etoposide resistance in human myeloma cells. Experimental Cell Research. 295(2). 421–431. 30 indexed citations

10.

Wang, Tianhong, Guilian Niu, Marcin Kortylewski, et al.. (2003). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine. 10(1). 48–54. 923 indexed citations breakdown →

11.

Hazlehurst, Lori, Terry H. Landowski, & William S. Dalton. (2003). Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 22(47). 7396–7402. 162 indexed citations

12.

Hazlehurst, Lori & William S. Dalton. (2001). Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies. Cancer and Metastasis Reviews. 20(1-2). 43–50. 132 indexed citations

13.

Ross, D D, Weidong Yang, Lynne V. Abruzzo, et al.. (1999). Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines. JNCI Journal of the National Cancer Institute. 91(5). 429–433. 284 indexed citations

14.

Catlett-Falcone, Robyn, Terry H. Landowski, Marc M. Oshiro, et al.. (1999). Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells. Immunity. 10(1). 105–115. 1408 indexed citations breakdown →

15.

Watts, George S., et al.. (1997). Methylation of Discrete Regions of the O ⁶ -Methylguanine DNA Methyltransferase (MGMT) CpG Island Is Associated with Heterochromatinization of the MGMT Transcription Start Site and Silencing of the Gene. Molecular and Cellular Biology. 17(9). 5612–5619. 192 indexed citations

16.

Wang, Hong, et al.. (1997). Decreased CP-1 (NF-Y) Activity Results in Transcriptional Down-Regulation of Topoisomerase IIα in a Doxorubicin-Resistant Variant of Human Multiple Myeloma RPMI 8226. Biochemical and Biophysical Research Communications. 237(2). 217–224. 22 indexed citations

17.

Dalton, William S.. (1994). Is p-glycoprotein a potential target for reversing clinical drug resistance?. Current Opinion in Oncology. 6(6). 595–600. 15 indexed citations

18.

Trent, Jeffrey M., Jinming Yang, Julia Emerson, et al.. (1993). Clonal chromosome abnormalities in human breast carcinomas II. Thirty‐four cases with metastatic disease. Genes Chromosomes and Cancer. 7(4). 194–203. 69 indexed citations

19.

Cress, Anne E., et al.. (1989). Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochemical Pharmacology. 38(23). 4283–4290. 20 indexed citations

20.

Bellamy, William, Robert T. Dorr, William S. Dalton, & David S. Alberts. (1988). Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.. PubMed. 48(22). 6360–4. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact